There are 150 resources available
Welcome and Introduction
Presenter: Eric Van Cutsem, Belgium; Josep Tabernero, Spain; Michel Ducreux, France
Session: Session I: Opening Session
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Presenter: Anthony B. El-Khoueiry, United States
Session: Session I: Opening Session
Resources:
Slides
First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
Presenter: Kei Muro, Japan
Session: Session I: Opening Session
Resources:
Slides
Discussant: LBA 0-9, LBA 0-10
Presenter: Ryan Corcoran, United States
Session: Session I: Opening Session
Resources:
Slides
Hereditary Predisposition to Pancreatic Cancer: Whom and How To Screen and What to Look For?
Presenter: Judith Balmaña, Spain
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Management of Pre-Malignant Pancreatic Lesions
Presenter: Pascal Hammel, France
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma
Presenter: Imen Ben-Ammar, France
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC - PRO
Presenter: Thomas Seufferlein, Germany
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC - CON
Presenter: Jordan Berlin, United States
Session: Session II: Cancer of the Pancreas
Resources:
Slides
Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC - DISCUSSION
Presenter: Thomas Seufferlein, Germany; Jordan Berlin, United States; Eric Van Cutsem, Belgium; Margaret Tempero, United States
Session: Session II: Cancer of the Pancreas